Dedifferentiated liposarcoma is a rare and aggressive form of soft tissue cancer that develops from an existing well-differentiated liposarcoma, typically appearing in adults over 50. Treatment approaches range from surgery and radiation to chemotherapy and innovative clinical trial therapies, each tailored to the individual’s specific situation.

Understanding Treatment Options for a Rare Cancer

Dedifferentiated liposarcoma, often abbreviated as DDLS, presents unique challenges when it comes to treatment. Unlike its slower-growing predecessor, well-differentiated liposarcoma, this cancer tends to grow quickly and has a higher likelihood of returning after treatment. The main goal of treatment is to remove the tumor completely, prevent it from coming back, and reduce the risk of it spreading to other parts of the body. Because each person’s cancer behaves differently depending on where it is located and how far it has progressed, treatment plans must be carefully customized.^[1]

Treatment decisions depend on several factors. The location of the tumor plays a crucial role—tumors in the arms or legs tend to have better outcomes than those developing in the retroperitoneum, which is the area at the back of the abdominal cavity. The size of the tumor, whether it has spread to nearby tissues or distant organs, and the patient’s overall health all influence which treatments will be most appropriate. Medical teams typically include surgeons, oncologists, radiation specialists, and pathologists who work together to create a comprehensive treatment strategy.^[2]

Standard treatments that have been approved and recommended by medical societies form the foundation of care for dedifferentiated liposarcoma. At the same time, researchers around the world are actively investigating new therapies through clinical trials. These studies test innovative drugs and treatment approaches that may offer hope for better outcomes in the future. Understanding both current standard treatments and emerging options helps patients and their families make informed decisions about their care.^[10]

Standard Treatment Approaches

Surgery as the Primary Treatment

Surgery remains the most important and reliable treatment for dedifferentiated liposarcoma. The goal of surgery is to remove the entire tumor along with a surrounding area of healthy tissue, known as taking a margin. This margin acts as a safety zone, capturing any cancer cells that might not be visible to the naked eye and reducing the chance of the cancer returning. Surgeons aim for margins of at least 10 millimeters when possible, though the exact amount depends on the tumor’s location and what structures surround it.^[1]

When tumors are located in the arms or legs, the surgical approach is usually more straightforward. The surgeon removes the tumor and surrounding tissue while preserving as much function as possible. In rare and severe cases where the tumor has grown extensively into nerves, blood vessels, or bone, amputation may be necessary, though this is uncommon. For tumors in the retroperitoneum, surgery becomes more complex because the tumor may be wrapped around or pressing against vital organs like the kidneys, intestines, or major blood vessels. These operations often require longer recovery times and carry higher risks.^[4]

After surgery, patients typically remain in the hospital for several days to a week or more, depending on the extent of the operation. Recovery at home may take several weeks to months. Physical therapy often plays an important role in helping patients regain strength and mobility, especially after surgery on a limb. The surgical specimen is always sent to a pathologist who examines it carefully to confirm the diagnosis and check whether the margins are clear of cancer cells.^[1]

Radiotherapy for Additional Control

Radiotherapy, also called radiation therapy, uses high-energy rays to kill cancer cells or prevent them from growing. It is sometimes used alongside surgery to improve outcomes in dedifferentiated liposarcoma. Radiation can be given before surgery to shrink the tumor and make it easier to remove, or after surgery to destroy any remaining cancer cells that might have been left behind. The decision to use radiation depends largely on the surgical margins—if the margin of healthy tissue around the tumor is less than 10 millimeters, radiation is often recommended.^[1]

Radiation therapy typically involves multiple sessions, usually five days a week for several weeks. Each session lasts only a few minutes, though the entire appointment may take longer due to preparation and positioning. The treatment itself is painless, similar to getting an X-ray. Side effects can occur and vary depending on where the radiation is directed. Common issues include skin irritation resembling a sunburn, fatigue, and localized swelling. When radiation is given to the abdomen, patients may experience nausea, diarrhea, or loss of appetite. Most side effects gradually improve after treatment ends.^[8]

Chemotherapy for Advanced Disease

Chemotherapy involves using drugs to kill cancer cells throughout the body. For dedifferentiated liposarcoma, the role of chemotherapy is less clear compared to surgery and radiation. Standard chemotherapy is most often used when the cancer has spread to distant organs or when it cannot be removed by surgery. The most common chemotherapy approach uses anthracyclines, particularly a drug called doxorubicin. This medication can be given alone or combined with another drug called ifosfamide, which belongs to a class of drugs known as alkylating agents.^[2]

The anthracycline-based regimen represents the standard first-line therapy for advanced dedifferentiated liposarcoma. However, the response rates have historically been modest, with studies showing that response occurs in roughly 12 to 24 percent of patients when combination chemotherapy is used. Other chemotherapy drugs that have shown some benefit include gemcitabine combined with docetaxel, trabectedin, eribulin, and pazopanib. Each of these medications works through different mechanisms to attack cancer cells, and the choice depends on factors like previous treatments, side effect profiles, and individual patient characteristics.^[7][9]

Chemotherapy is typically given in cycles, with treatment periods followed by rest periods to allow the body to recover. A single cycle might last two to three weeks, and multiple cycles are usually needed. The drugs are most often given through an intravenous line in the arm, though some can be taken as pills. Side effects vary depending on which drugs are used but commonly include nausea, vomiting, fatigue, hair loss, increased risk of infections due to lowered white blood cell counts, and potential effects on the heart and kidneys. Close monitoring with blood tests and other assessments helps doctors manage these side effects.^[10]

An ongoing debate among cancer specialists concerns whether chemotherapy should be used before surgery in patients with localized dedifferentiated liposarcoma. Some medical centers use neoadjuvant chemotherapy, meaning chemotherapy given before surgery, with the hope of shrinking the tumor and making it easier to remove. However, there is not yet clear evidence that this approach improves survival compared to surgery alone. Clinical trials are currently investigating this question to provide better guidance for future patients.^[1][8]

Innovative Treatments in Clinical Trials

Targeting Genetic Abnormalities

Scientists have made important discoveries about the genetic changes that drive dedifferentiated liposarcoma. Nearly all cases show amplification of a specific region of chromosome 12, known as 12q13-15. Amplification means that certain genes in this region are copied many times, producing too much of their protein products. The two most important genes in this region are MDM2 and CDK4. These genes normally help control cell growth and division, but when amplified, they push cells to grow uncontrollably and become cancerous.^[2]

This genetic knowledge has led researchers to develop drugs that specifically target MDM2 and CDK4. These targeted therapies represent a new frontier in treating dedifferentiated liposarcoma. CDK4 inhibitors work by blocking the activity of the CDK4 protein, which normally drives cells through their growth cycle. By inhibiting this protein, the drugs can slow or stop cancer cell division. Several CDK4/6 inhibitors, such as palbociclib and abemaciclib, have been tested in clinical trials for dedifferentiated liposarcoma.^[7]

MDM2 inhibitors take a different approach. The MDM2 protein normally keeps another protein called p53, which acts as a tumor suppressor, from working. By blocking MDM2, these inhibitors allow p53 to function properly and trigger cancer cell death. Early trials of MDM2 inhibitors have shown that while some patients experience tumor shrinkage, many others achieve prolonged stable disease, meaning the cancer stops growing even if it doesn’t shrink. This stability can extend survival and improve quality of life. However, response rates have been limited so far, typically ranging from 10 to 20 percent, and researchers continue working to understand why some patients respond while others do not.^[7]

Immunotherapy and the Immune System

Immunotherapy represents another promising avenue of research for dedifferentiated liposarcoma. These treatments work by helping the patient’s own immune system recognize and attack cancer cells. The most well-known type of immunotherapy involves immune checkpoint inhibitors, drugs that remove the brakes on immune cells, allowing them to fight cancer more effectively. Drugs like pembrolizumab and nivolumab block a protein called PD-1, while others block a related protein called PD-L1.^[7]

The challenge with immunotherapy in dedifferentiated liposarcoma is that these tumors are generally considered “cold,” meaning they don’t naturally attract many immune cells and don’t have many mutations that the immune system can recognize. This makes them less responsive to immunotherapy compared to some other cancers. However, researchers are investigating combination approaches that might “heat up” these cold tumors. For example, combining immunotherapy with radiation or with other drugs that promote immune cell infiltration into tumors might improve responses.^[7]

Clinical trials testing immunotherapy for dedifferentiated liposarcoma are ongoing in several countries, including the United States and European nations. These studies typically focus on patients whose cancer has spread or returned after standard treatments. Early results suggest that while most patients do not respond dramatically to immunotherapy alone, a small subset experiences significant benefit. Researchers are working to identify biomarkers—biological characteristics that can predict which patients are most likely to benefit from these treatments.^[7]

Phase Trials and What They Mean

Clinical trials progress through distinct phases, each designed to answer specific questions. Phase I trials focus primarily on safety, testing a new drug or treatment in a small group of patients to determine the best dose and identify side effects. These trials usually enroll between 15 and 30 people. Phase II trials evaluate whether the treatment actually works against the cancer. They involve larger groups, typically 30 to 100 patients, and measure outcomes like tumor shrinkage or time without disease progression.^[2]

Phase III trials compare the new treatment directly with the current standard treatment. These are large studies, sometimes involving hundreds of patients at multiple medical centers around the world. They provide the strongest evidence about whether a new therapy is truly better than existing options. If a Phase III trial shows clear benefit and acceptable side effects, the treatment may be approved by regulatory agencies and become available as a standard option for future patients.^[2]

For dedifferentiated liposarcoma specifically, many ongoing trials are in Phase I or II, testing the safety and early effectiveness of various targeted therapies and immunotherapies. Some Phase III trials have been completed or are underway comparing different chemotherapy combinations or testing whether adding targeted drugs to chemotherapy improves outcomes. Patients can find information about open clinical trials through their treatment centers, cancer organizations, or online registries that list studies recruiting participants.^[1]

Most Common Treatment Methods

• Surgery
  • Removal of the tumor with surrounding healthy tissue margins to reduce recurrence risk
  • Most reliable option for localized dedifferentiated liposarcoma
  • May involve complex procedures when tumors are in the retroperitoneum near vital organs
  • Rarely requires amputation in severe cases affecting limbs
• Radiotherapy
  • Used when surgical margins are less than 10 millimeters
  • Can be given before surgery to shrink tumors or after surgery to eliminate remaining cells
  • Typically delivered in daily sessions over several weeks
  • Side effects include skin irritation, fatigue, and localized symptoms depending on treatment area
• Chemotherapy
  • Standard first-line therapy uses anthracycline-based regimens, particularly doxorubicin
  • May be combined with ifosfamide for more aggressive treatment
  • Alternative regimens include gemcitabine with docetaxel, trabectedin, eribulin, and pazopanib
  • Response rates range from 12 to 24 percent with combination approaches
  • Given in cycles with rest periods between treatments
• Targeted Therapy
  • CDK4/6 inhibitors block proteins that drive cell division
  • MDM2 inhibitors allow tumor suppressor proteins to function properly
  • Based on genetic amplifications found in chromosome region 12q13-15
  • Primarily available through clinical trials
  • May produce stable disease even when tumors don’t shrink significantly
• Immunotherapy
  • Immune checkpoint inhibitors that remove brakes on immune system function
  • Includes drugs targeting PD-1 and PD-L1 proteins
  • Most effective when combined with other treatments due to “cold” tumor characteristics
  • Currently being tested in clinical trials for advanced or recurrent disease
  • Benefits only a subset of patients, with ongoing research to identify responders

Measuring Treatment Success and Follow-Up Care

Determining whether treatment is working requires careful monitoring through imaging tests and physical examinations. Doctors typically use something called RECIST criteria, which stands for Response Evaluation Criteria in Solid Tumors. This system measures changes in tumor size on CT or MRI scans. A partial response means the tumor has shrunk by at least 30 percent. Stable disease means the tumor hasn’t grown significantly but also hasn’t shrunk much. Progressive disease means the tumor has grown by 20 percent or more, or new tumors have appeared.^[9]

However, RECIST has limitations in dedifferentiated liposarcoma. These tumors are often large and heterogeneous, meaning different parts of the tumor may look and behave differently. Some treatments, particularly targeted therapies, may not cause tumors to shrink dramatically but can change their internal characteristics, making them less active or aggressive. Researchers have observed what they call “vascular response,” where the blood flow and appearance of blood vessels within the tumor change with treatment, even when the overall size doesn’t change much. These changes might indicate that the treatment is working in ways that RECIST doesn’t capture.^[9]

After treatment ends, regular follow-up is essential because dedifferentiated liposarcoma has a high rate of recurrence. A typical follow-up schedule includes appointments every three to six months for the first few years, then less frequently if no problems arise. Each visit includes a physical examination where the doctor checks for new lumps or symptoms. Imaging tests, usually MRI or ultrasound for tumors in the limbs, or CT scans for abdominal tumors, are performed regularly to check for recurrence. Catching a recurrence early often means more treatment options are available.^[1]

Patients should receive a follow-up schedule from their sarcoma clinical nurse specialist outlining exactly when appointments and scans should occur. This schedule may vary based on individual risk factors, such as the original tumor size, location, and whether margins were clear after surgery. Staying committed to follow-up care, even when feeling well, provides the best chance of detecting and addressing any problems early.^[8]